DelveInsight reports KRAS inhibitors market to grow positively by 2036
DelveInsight said the total KRAS inhibitors market size is expected to grow positively by 2036, driven by therapies such as Divarasib (RG6330), Olomorasib (LY3537982) and MK-1084. The company noted the United States accounted for the largest market share in 2025, with 539,400 incident NSCLC cases.
Primary source
Company press release (PR Newswire), October 19, 2026
KRAS Inhibitors Market is Set for Expansion During the Forecast Period (2026-2036) Supported by Emerging Therapies Targeting Diverse KRAS Mutations | DelveInsight
Machine-summarized from the source above; not independently reported. How we use automation